0K91 Stock Overview
A biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Quantum BioPharma Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$4.32 |
| 52 Week High | CA$63.83 |
| 52 Week Low | CA$3.17 |
| Beta | 0.76 |
| 11 Month Change | 3.85% |
| 3 Month Change | -5.68% |
| 1 Year Change | -93.23% |
| 33 Year Change | -93.31% |
| 5 Year Change | -98.41% |
| Change since IPO | -99.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0K91 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -9.6% | 1.2% | 1.3% |
| 1Y | -93.2% | -19.7% | 7.9% |
Return vs Industry: 0K91 underperformed the German Pharmaceuticals industry which returned -19.7% over the past year.
Return vs Market: 0K91 underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 0K91 volatility | |
|---|---|
| 0K91 Average Weekly Movement | 19.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0K91's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0K91's weekly volatility has decreased from 51% to 20% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 17 | Zeeshan Saeed | www.fsdpharma.com |
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Quantum BioPharma Ltd. Fundamentals Summary
| 0K91 fundamental statistics | |
|---|---|
| Market cap | €8.42m |
| Earnings (TTM) | -€9.67m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs 0K91 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0K91 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.24m |
| Earnings | -US$10.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -5.33 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.0% |
How did 0K91 perform over the long term?
See historical performance and comparison